Safety and Effectiveness of Early Feeding After Bowel Anastomosis in Neonates or Infants
Launched by WEIBING TANG · Jul 7, 2020
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
Intestinal anastomosis is a common operation for the treatment of digestive tract diseases of newborns and infants. It is not be defined that when should begin oral feeding after intestinal anastomosis. Poor anastomotic healing or anastomotic leakage is the most serious complication after intestinal anastomosis, which often leads to severe abdominal infection, peritonitis and even death. Nowadays, it is believed that the causes of poor anastomotic healing or anastomotic leakage are various, including contaminated during the operation, the blood supplyment of the bowel edges at both ends of ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (1)neonates or infants less than 12 months (2)Intestinal anastomosis, including small intestine and colon anastomosis
- Exclusion Criteria:
- • (1) Premature infants or children with a weight of less than 2.5 kg during surgery are excluded (2) Exclude cases of severe abdominal infection (3) Exclude cases of severe imbalance of the proximal and distal intestinal canal of the anastomosis (such as intestinal atresia)
About Weibing Tang
Weibing Tang is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes, the organization specializes in the design, management, and execution of clinical trials across various therapeutic areas. Leveraging a robust network of clinical sites and a team of experienced professionals, Weibing Tang ensures compliance with regulatory standards while prioritizing patient safety and data integrity. The sponsor is driven by a mission to facilitate the development of transformative therapies that address unmet medical needs, ultimately contributing to the improvement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xuzhou, Jiangsu, China
Hefei, Anhui, China
Patients applied
Trial Officials
Weibing Tang, Dr
Study Director
Children's Hospital of Nanjing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials